河化股份(000953) - 2021 Q1 - 季度财报

Financial Performance - Revenue for Q1 2021 was CNY 46,757,837.67, a decrease of 21.97% compared to CNY 59,919,555.56 in the same period last year[7] - Net profit attributable to shareholders was CNY 5,459,994.36, down 37.05% from CNY 8,672,939.51 year-on-year[7] - Net profit excluding non-recurring gains and losses was CNY 4,511,985.86, a decline of 47.11% compared to CNY 8,530,236.73 in the previous year[7] - Total operating revenue for Q1 2021 was CNY 46,757,837.67, a decrease of 21.9% compared to CNY 59,919,555.56 in the same period last year[34] - Net profit for Q1 2021 was CNY 5,987,334.49, a decline of 36.1% from CNY 9,460,412.29 in Q1 2020[35] - The company's gross profit margin for Q1 2021 was approximately 12.5%, compared to 20.1% in Q1 2020[34] - The total profit for the first quarter was -2,085,639.26 CNY, an improvement from -2,589,628.39 CNY in the previous year, indicating a reduction in losses by approximately 19.5%[39] Cash Flow - Operating cash flow net amount was CNY 2,363,926.60, a significant drop of 86.88% from CNY 18,019,109.23 in the same period last year[7] - Net cash flow from operating activities decreased by 15.6552 million yuan, a decline of 86.88%, mainly due to reduced sales collections in the current period[16] - Cash inflow from sales of goods and services was 44,958,056.42 CNY, compared to 97,273,784.54 CNY in the previous year, representing a decline of approximately 53.8%[41] - The net cash flow from investing activities was 27,810,560.23 CNY, a significant turnaround from -19,966,081.44 CNY in the previous year, indicating a positive change in investment cash flow[42] - The company’s cash flow from financing activities was -419,812.49 CNY, compared to a positive inflow of 112,586,801.07 CNY in the same period last year, indicating a shift in financing strategy[42] - The cash outflow for purchasing goods and services was 35,564,721.21 CNY, compared to 69,746,330.52 CNY in the previous year, a reduction of about 49.1%[42] Assets and Liabilities - Total assets increased by 5.45% to CNY 396,787,379.14 from CNY 376,292,912.19 at the end of the previous year[7] - Total current assets as of March 31, 2021, amounted to 149.968 million yuan, an increase from 127.499 million yuan as of December 31, 2020[26] - Total assets as of March 31, 2021, were 396.787 million yuan, compared to 376.293 million yuan as of December 31, 2020[28] - Total liabilities as of March 31, 2021, were 208.374 million yuan, an increase from 193.867 million yuan as of December 31, 2020[28] - The total liabilities as of the end of Q1 2021 were CNY 167,029,534.43, an increase from CNY 165,139,066.89 at the end of the previous quarter[32] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 15,518[11] - The company’s total equity as of the end of Q1 2021 was CNY 116,465,100.02, down from CNY 118,550,739.28 in the previous quarter[32] - The company reported a net loss of 711.074 million yuan in retained earnings as of March 31, 2021, compared to a loss of 716.534 million yuan as of December 31, 2020[28] Expenses - Operating costs decreased by 7.9194 million yuan, a decline of 19.87%, mainly due to increased sales of pharmaceutical intermediates last year caused by the pandemic[16] - Management expenses increased by 1.5624 million yuan, up 38.79%, primarily due to maintenance of the production system during the current period[16] - Research and development expenses for Q1 2021 amounted to CNY 1,749,251.19, slightly down from CNY 1,806,866.65 in the previous year[35] - The company reported a decrease in management expenses to CNY 5,590,043.98 from CNY 4,027,612.01 in the previous year[35] Inventory and Receivables - Accounts receivable increased by CNY 15,787,500, up 207.23%, due to increased product sales with outstanding payments[15] - Inventory decreased by CNY 9,006,400, down 33.86%, attributed to increased sales volume leading to reduced stock[15] - Contract liabilities increased by CNY 13,094,200, up 338.36%, due to increased prepayments from customers for fertilizer purchases[15] Other Information - The company did not report any new product developments or market expansions during this quarter[45]